Original article on AP News
QR-421a showed early and encouraging evidence of activity, with 25% of patients showing a benefit across multiple concordant outcome measures and was well tolerated with no serious adverse events — QR-421a is the second ophthalmology program where clinical activity was predicted by translational models, further validating the platform — COVID-19 pandemic expected to impact timelines for the pipeline — ProQR anticipates its cash runway will fund operations into H2 2022
LEIDEN, Netherlands & CAMBRIDGE, Mass.,
Read ProQR is developing a novel investigational drug called QR-421a to treat RP in patients that have USH2 due to a mutation in a specific part of the USH2A gene, called exon 13.
Read